Coronavirus channel feed

Lat­est Covid-19 shots are al­most ready: Why is the US au­tho­riz­ing a dif­fer­ent boost­er than the rest of the world?

3 years ago

Covid-19 roundup: Mod­er­na gets Swiss boost­er OK; Bi­va­lent shots ex­pect US EUA sans com­plete in-hu­man da­ta — re­port

3 years ago

As­traZeneca’s Pas­cal So­ri­ot says Covid-19 boost­ers may not be for every­one — re­port

3 years ago

Pfiz­er's Paxlovid on­ly helped se­niors avoid hos­pi­tal­iza­tion and death, new NE­JM study finds

3 years ago

In­ovio agrees to shell out $44M to set­tle Covid-19 vac­cine law­suit

3 years ago
Pharma
Law

House in­ves­ti­gates Trump’s ‘in­ap­pro­pri­ate’ pres­sure on FDA dur­ing the pan­dem­ic

3 years ago
FDA+

Covid-19 roundup: Bi­va­lent vac­cines to be au­tho­rized by La­bor Day — re­port; Mod­er­na knocks on FDA's door for boost­ers

3 years ago

Covid-19 roundup: Pfiz­er/BioN­Tech add on vac­cine da­ta for young chil­dren; Mex­i­co says it's miss­ing vac­cine dos­es from UN

3 years ago

Covid-19 roundup: Pfiz­er sub­mits EUA for Omi­cron-tar­get­ed boost­er; No­vavax EUA ex­pands to teens

3 years ago

Covid-19 roundup: EMA starts re­view of SK’s vac­cine; Aus­tralian biotech switch­ing gears away from Covid re­search

3 years ago

New Hahn-era texts show the ex­tent of the Trump White House­'s in­volve­ment in vac­cine EUA process

3 years ago
FDA+

UK says it won't pur­chase As­traZeneca's Covid treat­ment due to 'in­suf­fi­cien­t' Omi­cron da­ta — re­ports

3 years ago
Pharma

Mod­er­na's bi­va­lent Omi­cron vac­cine se­cures reg­u­la­to­ry OK in UK

3 years ago
Pharma

More than half a bil­lion Covid vac­cine dos­es wast­ed af­ter Emer­gen­t's Bal­ti­more fi­as­co

3 years ago
Manufacturing

De­mand-con­strained Covid vac­cine mar­ket may push South Africa's As­pen to change its di­rec­tion

3 years ago
Manufacturing

Af­ter FDA re­vokes EUA for GSK-part­nered mAb, Vir changes its plans on Covid-19 treat­ments

3 years ago
R&D

Covid-19 roundup: De­sert­ed by Roche and plagued by set­backs, Atea march­es on; Eu­rope lines up or­der for Mod­er­na's Omi­cron boost­er

3 years ago

US to stop sup­ply­ing Lil­ly's mAb for Covid-19 this month as com­mer­cial mar­ket awaits

3 years ago
Pharma

Ake­bi­a's ane­mia drug flunked Covid study — but count the bruised biotech 'ex­treme­ly en­cour­aged'

3 years ago
R&D

Green­Light Bio­sciences cel­e­brates man­u­fac­tur­ing mile­stone for Covid-19 boost­er can­di­date

3 years ago
Pharma
Manufacturing

Ax­cel­la flunks long Covid PhII pri­ma­ry goal — but plots a path in­to PhI­II

3 years ago
R&D

Re­gen­eron ends four clin­i­cal tri­als of its rolled-back Covid-19 an­ti­body

3 years ago
R&D
Pharma

Covid-19 roundup: Mod­er­na, US sign con­tract for au­tumn boost­er dos­es; Enan­ta touts PhI re­sults for its an­tivi­ral

3 years ago

Tonix will test its mon­key­pox vac­cine in Kenya next year, and no eyes on ac­cel­er­at­ed path at FDA

3 years ago
R&D
First page Previous page 567891011 Next page Last page
A service from the Financial Times